EP4743123A1 - ANTI-HUMAN CENG1 ANTIBODY CONJUGATES AND USES THEREBY - Google Patents
ANTI-HUMAN CENG1 ANTIBODY CONJUGATES AND USES THEREBYInfo
- Publication number
- EP4743123A1 EP4743123A1 EP23822163.4A EP23822163A EP4743123A1 EP 4743123 A1 EP4743123 A1 EP 4743123A1 EP 23822163 A EP23822163 A EP 23822163A EP 4743123 A1 EP4743123 A1 EP 4743123A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ceng1
- human
- antibody conjugates
- conjugates
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363512814P | 2023-07-10 | 2023-07-10 | |
| PCT/US2023/078684 WO2025014533A1 (en) | 2023-07-10 | 2023-11-03 | Anti-human cacng1 antibody-drug conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4743123A1 true EP4743123A1 (en) | 2026-05-20 |
Family
ID=89190862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP23822163.4A Pending EP4743123A1 (en) | 2023-07-10 | 2023-11-03 | ANTI-HUMAN CENG1 ANTIBODY CONJUGATES AND USES THEREBY |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4743123A1 (en) |
| KR (1) | KR20260038279A (en) |
| CN (1) | CN121568720A (en) |
| AU (1) | AU2023454911A1 (en) |
| CO (1) | CO2026001291A2 (en) |
| IL (1) | IL325400A (en) |
| MX (1) | MX2026000414A (en) |
| WO (1) | WO2025014533A1 (en) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| ES2731432T3 (en) | 2007-05-23 | 2019-11-15 | Ventana Med Syst Inc | Polymeric transporters for immunohistochemistry and in situ hybridization |
| RU2487877C2 (en) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Potent conjugates and hydrophilic cross-linking agents (linkers) |
| WO2010010324A1 (en) | 2008-07-21 | 2010-01-28 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| LT2975051T (en) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | EASY-RELEASED BIS-SPECIFIC ANTIBODIES TO NATIVE IMMUNOGLOBULIN |
| WO2011018613A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Functionalisation of solid substrates |
| HRP20151188T4 (en) | 2010-02-08 | 2021-10-01 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| LT2738259T (en) | 2011-02-25 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | ADAM6 MOUSE |
| EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| MX358757B (en) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pyrrolobenzodiazepines and targeted conjugates. |
| SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| AU2012348017A1 (en) | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| PT3527070T (en) | 2011-12-20 | 2025-12-19 | Regeneron Pharma | Humanized light chain mice |
| ES2659270T5 (en) | 2012-10-23 | 2026-02-11 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
| TWI682941B (en) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | Antibodies comprising chimeric constant domains |
| US11786603B2 (en) | 2016-02-26 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| KR20250114431A (en) * | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | Steroids and protein-conjugates thereof |
| US11952349B2 (en) * | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4171653A2 (en) | 2020-06-24 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| US20250017183A1 (en) * | 2021-11-04 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
| KR20240095211A (en) * | 2021-11-04 | 2024-06-25 | 리제너론 파마슈티칼스 인코포레이티드 | Viral particles retargeted to skeletal muscle |
| WO2023143208A1 (en) | 2022-01-26 | 2023-08-03 | 苏州宜联生物医药有限公司 | Preparation method for drug linker conjugate |
-
2023
- 2023-11-03 IL IL325400A patent/IL325400A/en unknown
- 2023-11-03 EP EP23822163.4A patent/EP4743123A1/en active Pending
- 2023-11-03 AU AU2023454911A patent/AU2023454911A1/en active Pending
- 2023-11-03 WO PCT/US2023/078684 patent/WO2025014533A1/en not_active Ceased
- 2023-11-03 KR KR1020267004067A patent/KR20260038279A/en active Pending
- 2023-11-03 CN CN202380100260.3A patent/CN121568720A/en active Pending
-
2026
- 2026-01-09 MX MX2026000414A patent/MX2026000414A/en unknown
- 2026-02-05 CO CONC2026/0001291A patent/CO2026001291A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20260038279A (en) | 2026-03-18 |
| WO2025014533A1 (en) | 2025-01-16 |
| CN121568720A (en) | 2026-02-24 |
| MX2026000414A (en) | 2026-03-02 |
| CO2026001291A2 (en) | 2026-02-23 |
| AU2023454911A1 (en) | 2026-01-22 |
| IL325400A (en) | 2026-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4426741A4 (en) | MONOCLONAL BCMA ANTIBODIES AND ANTIBODIES CONJUGATE | |
| EP4085076C0 (en) | BCMA-binding antibodies and uses thereof | |
| IL290979A (en) | Antibody-drug conjugates containing anti-human ror1 antibody and use thereof | |
| EP4499707A4 (en) | Anti-CCR8 antibodies and their uses | |
| EP4139347A4 (en) | ANTI-CD3 ANTIBODIES AND USES THEREOF | |
| EP4359442A4 (en) | ANTI-CCR8 ANTIBODIES AND USES THEREOF | |
| EP4051711A4 (en) | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | |
| EP4299589A4 (en) | ANTI-HUMAN CD73 ANTIBODIES AND USE THEREOF | |
| EP4142793A4 (en) | ABCB5-SPECIFIC ANTIBODIES AND USES THEREOF | |
| EP4126938A4 (en) | SIGLEC15-BINDING ANTIBODIES AND USES THEREOF | |
| EP4223777A4 (en) | ANTI-CD3 ANTIBODIES AND USES THEREOF | |
| EP4244255A4 (en) | ANTI-TIGIT ANTIBODIES AND USES THEREOF | |
| EP4341297A4 (en) | NEW ANTI-CD276 ANTIBODIES AND THEIR USES | |
| EP4132569A4 (en) | ANTI-PHF-TAU ANTIBODIES AND USES THEREOF | |
| IL300176A (en) | Anti-CD228 antibodies and antibody-drug conjugates | |
| EP4247419A4 (en) | ANTI-MARCO ANTIBODIES AND USES THEREOF | |
| EP4159859A4 (en) | ANTI-HUMAN NR1 ANTIBODY DERIVATIVE | |
| PL4274851T3 (en) | ANTI-GPRC5D MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS | |
| EP4396224A4 (en) | ANTI-DLL3 ANTIBODIES AND USES THEREOF | |
| EP4146272A4 (en) | COVID-19 ANTIBODIES AND USES THEREOF | |
| EP4437002A4 (en) | ANTI-HSP90? ANTIBODIES AND THEIR USES | |
| EP4415727A4 (en) | Chimeric anti-STEAP2 antigen receptors and uses thereof | |
| EP4431521A4 (en) | ANTIBODIES CONJUGATE AND USES THEREOF | |
| EP4373856A4 (en) | ANTI-CLL-1 ANTIBODIES AND USES THEREOF | |
| EP4511400A4 (en) | Antibodies directed against SIRP-alpha and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |